Stefan Kasper-Virchow

14PUBLICATIONS
113CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)AllergyPacific Peoples sport and physical activity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jan 05, 2026
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Julius Keyl, René Hosch, Fabian Hörst

|Jul 30, 2025
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Apr 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Jérôme Fayette, Lisa Licitra, Kevin Harrington

|Jun 14, 2024
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.

Thomas Seufferlein, Ludwig Lausser, Alexander Stein

|Jan 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).

Arndt Stahler, Andreas J Kind, Christine Sers

|Oct 18, 2023
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil

Pageof 3

Frequent Collaborators

4 joint publications

Martin Schuler

3 joint publications

Tanja Trarbach

3 joint publications

Sebastian Stintzing

3 joint publications

Annika Kurreck